ACHIEVING OUR MISSION THROUGH FUNDING INDUSTRY:
UPDATE TO CIRM STRATEGIC PLAN

Organized Pursuant To Government Code section 11346.5(a)(17)
and
The CALIFORNIA STEM CELL RESEARCH AND CURES ACT

Dates and Locations

• Tuesday, February 3, 2009, Northern California

• Friday, February 20, 2009, Southern California

See the Flyer for location and RSVP details 

Agenda

1. CIRM Update – Alan Trounson, President, CIRM

                a.  Overview of CIRM's goals (per Prop 71)

                b.  Breakdown of allocation of CIRM grants to date:

                c.  Bricks & mortar vs. research and basic vs. translational

                d.  Quick overview of upcoming RFA's

                e.  Here is how companies get money from CIRM today

1. Presentation on Financial State of the Regenerative Medicine Sector - Jeff Karan, Proteus
2. Q&A - Moderated by Ed Penhoet, ICOC

Questions

• What are the biggest challenges faced by commercial participants in this sector?
• What should the basic/translational/clinical balance of CIRM’s portfolio be today in order to reach the goals set out in Prop. 71? 18 months from now? Three/five years from now?
• What form should CIRM funding to companies take? Should there be company specific RFAs? Should there be something like SBIRs? Is there a preference between loans (recourse and non-recourse) and grants?
• Do reimbursement uncertainties impact your evaluation of financial opportunities presented by this sector? Should CIRM take a significant role in the discussion around placing a reimbursement value on “cures?”
• Given that many of CIRM’s policies and regulations are locked in by law, are there any of them that are causing significant blocks to our strategic goals and are there ways to make adjustments to those policies and stay within the framework of the Prop 71 statute.

Supporting Documents:

• Draft 2009 Revised Strategic Plan - Industry Section
• 2006 Scientific Strategic Plan - Executive Summary

THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.
Notice is hereby given that the order of consideration of matters on this agenda may be changed without prior notice.

**NOTICE**

The California Institute for Regenerative Medicine and its Independent Citizens Oversight Committee, and any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the Members of the Committee is available to the public in appropriate alternative formats when requested. If you need further assistance, including disability-related modifications or accommodations, you may contact Melissa King at the California Institute for Regenerative Medicine at 415-396-9100 no later than the day prior to the meeting.

Questions or requests for additional information prior to the Independent Citizens Oversight Committee meeting may be referred to Melissa King at the California Institute for Regenerative Medicine at mking@cirm.ca.gov or 415-396-9100.

This meeting agenda is also available on the website for the California Institute for Regenerative Medicine at http://www.cirm.ca.gov.